Running Title: Acquired immune resistance following a complete response
Introduction
Immunotherapy of cancer frequently results in durable clinical responses. However, a significant fraction of patients who initially respond will experience renewed tumor progression. So far, it is reported that about 30% of patients responding to checkpoint inhibitors (1, 2) and about 60% of patients responding to cellular immunotherapy with tumor-infiltrating lymphocytes (TILs) (3) will experience disease progression respectively within two years and within five years. With increasing availability of immunotherapies, disease progression after initial clinical response or treatmentinduced immune resistance is rapidly emerging as a major hurdle in oncology practice(4).
It is generally believed that processes leading to acquired immune resistance would practically overlap to mechanisms involved in naturally acquired resistance during primary immunoediting (5) .
Current knowledge on disease progression after initial response to immunotherapy is derived from comprehensive animal models, or clinical anecdotes which associate certain disease features to renewed disease progression (4). In a recent publication, Verdegaal and co-authors (6) elegantly show how immunogenic neo-antigens can be lost or downregulated during tumor progression. In this study, the authors used multiple samples from two patients with melanoma, including one patient treated with adoptive cellular therapy before collection of a progressing lesion. However, none of the samples analyzed was obtained after a true immune-mediated tumor regression, but rather during the natural progression of human melanoma or very short disease stabilization following T cell-based immunotherapy. Therefore, the relevance of these findings may be limited to the situation of prolonged immunological interactions of tumors with the adaptive immune system, Research. on July 16, 2018. © 2017 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/0008-5472. in the absence of elimination of large tumor masses. In another study, Zhao and co-authors (7) described the case of a patient with metastatic melanoma and multiple recurrent lesions, where poorly immunogenic melanoma phenotypes evolve toward T cell resistance by independent genetic events leading to MHC class I loss/deficiency. Again, this patient was treated with various forms of immunotherapy but did not appear to experience a clear immune-mediated tumor regression. In contrast, novel cancer immunotherapies frequently induce tumor regressions developing in few weeks to few months but, however, in a significant fraction of patients this initial clinical response does not last. Zaretsky and co-authors (8) described four patient cases who progressed while receiving anti-PD-1 immunotherapy, after an initial partial tumor regression. They identified defective IFN- signaling and inactivation of 2 microglobulin as mechanisms of acquired resistance to immunotherapy.
Here, we present mechanistic evidence of clinical tumor immune escape in an exemplary clinical case of a patient with metastatic melanoma, who developed disease recurrence following an unequivocal initial radiologic complete tumor regression to cellular immunotherapy with autologous TILs. Given the nature of this treatment, the infusion product which induced tumor regression could be studied in detail with antigen-specific assays and tests of direct tumor recognition and killing. Disease recurrence was not associated with cancer cells that lost target antigens or had impaired IFN- signaling, but with cancer cells with defective MHC class I antigen processing and presentation machinery (APM).
Research.
on July 16, 2018. © 2017 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/0008-5472.CAN- 
Materials and Methods

Patient treatment and clinical specimens
All the procedures were approved by the Scientific Ethics Committee for the Capital Region of in the context of the clinical trial NCT00937625, and TILs were prepared accordingly as described in (9) . Melanoma cell lines were established as described in (10) at the Center for Cancer Immune Therapy, Herlev Hospital, Denmark.
TILs were established according to standard methods, as described by Ellebaek E et al. (9) . Briefly, TILs were initially isolated and minimally expanded (mcTILs, as in(10)) from tumor fragments in standard complete medium supplemented with IL-2 (6000 IU/ml IL-2, Proleukin, Novartis) and subsequently were massively expanded according to the Rapid Expansion Protocol (REP). PBMCs were isolated from a blood sample with gradient centrifugation, and stored according to local standard operating procedures. All melanoma cell lines,were generated by serial passage of adherent cells released from tumor fragments and cultured in RPMI 1640 (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FCS (Life Technologies), as previously described (11) .
The time points for collection of tumor samples (used for generation of TILs and melanoma cell lines) and PBMCs are indicated in Figure 1A . Briefly, tumor #1 was resected in February 2011, and both TIL#1 and Mel#1 were established from this sample; TIL#1 were infused in July 2011, and
Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/0008-5472. this treatment resulted in a complete response according to RECIST 1.0; PBMCs were collected at serial time points; tumor #2, first identified with a PET/CT scan in August 2012 was resected in September 2012, and both TIL#2 and Mel#2 were established from this sample.
Analysis of T-cell responses
All peptides were obtained from the NKI peptide synthesis facility (Amsterdam, The Netherlands)
or Pepscan (Lelystad, The Netherlands). Combinatorial encoding with peptide(p)-MHC multimers was carried out with TIL#1 and TIL#2 to identify T cell specific for shared antigens, as described in (12) . One initial screening to detect CD8 + T cells in TIL#1 recognizing mutant antigens for the patient specific HLA alleles of Mel#1 was carried out as described in supplementary methods and previously used in (13) . Additional focused screenings to identify whether mutant antigens privately expressed in Mel#1 were recognized was conducted by stimulating TIL#1 and TIL#2 with short peptides (8-11 mers) in overnight IFN- ELISPOT assays. ELISPOT were carried out as previously described(10), using 23 additional potential private neo-epitopes of Mel#1, identified as described below (9 other private neo-epitopes were already tested in the primary screening and thus were not analyzed). Prediction of neo-epitopes is described in the supplementary file. Positive responses were confirmed with intracellular staining of TNF and IFN- after stimulation of TIL#1 or TIL#2 (criteria for evaluation of positive responses were as in (11)). Responses were observed to the peptides RLSNRLLLR (TAG RLS , HLA-A3, >2% of CD8 + T cells in TIL#2) and three of four tested peptides derived from the LRCH1 p.E672K mutation (CLPHHILEKK, HLA-A*03:01, >2% of In all other cases, evaluation of T-cell responses was performed as previously described (11) with tumor reactivity evaluated by assessing the amount of CD8 + T cells co-expressing TNF and IFN-.
FACS antibodies were obtained from BD Biosciences, unless indicated otherwise. Where indicated, tumor cells were pre-treated with 100 IU/ml of recombinant human IFN- (Peprotech) for 72 hours.
The chromium-51 cytotoxicity assay was performed as previously described (15) .
Gene and protein expression of tumor cells
Analysis of mRNA and proteins (western blot) on selected APM components and putative target antigens were performed as recently described (16) . Briefly, for mRNA analysis the cDNA was Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/0008-5472.CAN- staining was detected with horseradish peroxidase (HRP) -conjugated secondary antibodies (Dako, Hamburg, Germany). The membranes were washed and protein bands were visualized with a Lumilite (Roche Diagnostics, Mannheim, Germany) and exposed to a CCD camera (Eastman Kodak, Berlin, Germany).
Results and Discussion
The initial complete response following infusion of autologous TILs generated from an initially resected tumor metastases (TIL#1 and tumor#1) is reported in Ellebaek et al. (9) . Recurrent metastatic disease (tumor#2) was diagnosed about 1 year after primary treatment (summary of the clinical history is shown in Figure 1A ).
CD8 + T cells recognizing one neo-antigen derived from the mutation LRCH1 p.E672K (LRCH1 E>K ) and the cancer-testis antigen (epitope TAG RLS ) ( Figure 1B , left panel) were identified in minimally cultured (mc) TIL#1. About 6% of CD8 + T cells in the infusion product, derived from TIL#1, recognized the unedited melanoma (Mel#1) in vitro, including T cells recognizing LRCH1 E>K and TAG RLS which alone corresponded to up to about 60% of the total tumor reactivity of peripheral CD8 + T cells one week after infusion ( Figure 1C ). Therapy-induced tumor-reactive/specific CD8 + T cells detected peripherally persisted beyond tumor re-growth ( Figure 1C ). mcTIL#2, isolated from the recurrent tumors (tumor#2, from which the cell line Mel#2 was generated), contained at least comparable frequencies of tumor-reactive/specific T cells, including three-fold higher percentages of CD8 + T cells recognizing LRCH1 E>K (Figure 1B and 1C) . In mcTIL#2, CD8 + T cells recognizing TAG RLS or LRCH1 E>K did not express higher levels of co-inhibitory molecules such as PD-1, LAG-3 or TIM-3 ( Supplementary Figure S1A and S1B). Thus, tumor re-growth occurred despite effective Over 80% of non-synonymous and synonymous mutations detected were identical in tumor#1, Mel#1 and Mel#2 ( Supplementary Table S1 ), including the LRCH1 E>K mutation ( Figure 1D ). However, while tumor#1 and Mel#1 expressed both the mutant and wild-type alleles, Mel#2 only harbored (DNA - Figure 1D ) and expressed (RNAdata not shown) the mutant allele, and at a slightly higher level as compared to Mel#1 ( Figure 1E ). No dramatic reduced expression of the other known target antigen TAG (Supplementary Figure S2A) as well as additional putative target antigens, such as common melanocyte differentiation antigens and cancer-testis antigens with the exception of MAGE-4 ( Supplementary Figure S2B) , were found. However, it is important to highlight that no responses to other putative antigens were detected with the screening methods employed (see materials and methods/Analysis of T cell responses). Although Mel#1 harbored multiple putative neo-antigens that were absent in Mel#2, further focused screening efforts did neither identify CD8 + T cells in TIL#1 and TIL#2 recognizing these candidate neo-antigens (data not shown). No increased expression of the immune suppressive PD-L1 was observed in Mel#2 (Supplementary Figure S2C) . Importantly, Mel#2 displayed multiple newly emerged defects in the MHC class I APM ( Figure 1F for protein and Supplementary Figure S2D where B2M is located, shows no evidence of LOH in both Mel#1 and Mel#2 (Supplementary Figure   S3D ). Overall, a specific genetic or epigenetic event to explain the observed immune resistant phenotype could not be identified either at DNA ( Supplementary Table S1 ) or RNA (Supplementary Figure S4) level.
In parallel, recognition of Mel#2 by unselected TILs (Supplementary Figure S5A and S5B for cytokine production; TIL#1 in Figure 1G MHC class I APM deficient tumors can be hardly targeted effectively by immunotherapies stimulating CD8 + T cell responses (18) . Impaired MHC class I APM may represent a universal mechanism of resistance to CD8 + T cell responses targeting any tumor-antigen (19) , and a dichothomy with higher MHC class I APM expression in regressing compared to progressing metastases was observed in other studies as well (20) . In order to prevent or treat tumor recurrences with acquired MHC class I APM deficiency, we suggest that alternative strategies such as restoring APM via targeted-delivery of APM-inducers, or non-T cell based immune strategies should be tested. In sum, these data together with recent works by Zaretsky and co-authors Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
